A newly-announced collaboration with JDRF, Aspect Biosystems is ramping up the development of a 3D printed tissue therapy for treating type 1 diabetes. While the firm hasn’t revealed exactly how the treatment will work, it’s understood to be a cell-based implant that works to repair damaged organ functions, thus making patient insulin injections obsolete.
3D bioprinting firm Aspect Biosystems is set to work with diabetes research group JDRF to develop a tissue therapy for type 1 diabetics.